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and over the counter pediculicide treatments against head lice in the
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N Hill, G Moor, M M Cameron, A Butlin, S Preston, M S Williamson, C Bass
Abstract
Objective To compare the effectiveness of the Bug Buster kit
with a single treatment of over the counter pediculicides for
eliminating head lice.
Design Single blind, multicentre, randomised, comparative
clinical study.
Setting Four counties in England and one county in Scotland.
Participants 133 young people aged 2-15 years with head louse
infestation: 56 were allocated to the Bug Buster kit and 70 to
pediculicide treatment.
Interventions Home use of proprietary pediculicides
(organophosphate or pyrethroid) or the Bug Buster kit.
Main outcome measure Presence of head lice 2-4 days after
end of treatment: day 5 for the pediculicides and day 15 for the
Bug Buster kit.
Results The cure rate using the Bug Buster kit was significantly
greater than that for the pediculicides (57% v 13%; relative risk
4.4, 95% confidence interval 2.3 to 8.5). Number needed to treat
for the Bug Buster kit compared with the pediculicides was
2.26.
Conclusion The Bug Buster kit was the most effective over the
counter treatment for head louse infestation in the community
when compared with pediculicides.
Introduction
Infestation with head lice, Pediculosis capitis, is a widespread, per-
sistent, and recurring problem and although it poses no direct
threat to health, it may lead to secondary infections if untreated.1
The mere presence of head lice may cause distress to children
and their families.2 3 Previous studies of insecticides have
reported treatment failure in laboratory bioassays4–9 and field tri-
als.4 5 9 10 Systematic reviews have identified several flaws in earlier
study designs,11 12 and a clinical review of best practice compared
the merits of each class of pesticide currently available.13 Several
possible mechanisms for resistance in head lice have been
reported.4 5 9 14 Treatment failure is likely to be an important fac-
tor in the reported rise in the incidence of head lice infestation,
but of concern is the increased risk of toxicity this may pose to
children. Although current insecticides registered for use against
head lice are generally considered safe for occasional use,15 they
may pose a greater risk of direct or cumulative toxicity if used
frequently.
Wet combing with conditioner was first developed as a
method of detecting head lice and was subsequently advocated
as a means of treatment (“Bug Busting”) by the UK charity Com-
munity Hygiene Concern.16 The method involves using a fine
toothed comb on thoroughly wet hair. Over several years the
charity has developed and trialled a Bug Buster kit comprising
instructions and materials to undertake four sequential
combings on wet, conditioned hair, leaving three days between
each.2 A recent Cochrane review highlighted the need for a clini-
cal evaluation of the kit.11 The only randomised controlled trial to
date was carried out in two Welsh counties, an area with head lice
showing intermediate resistance to treatment.10 The cure rate for
the kit was only 38% compared with 78% for two doses of 0.5%
malathion lotion six days apart.10 This early study used a
prototype kit (1996 version), which has since undergone major
developments in the design of the comb for removing small
nymphs. We compared the effectiveness of the current (1998)
Bug Buster kit with over the counter pediculicides containing
malathion or permethrin among representative populations
from four counties in England and one county in Scotland. We
aimed to measure the effectiveness of the treatments under real-
istic conditions, as used by people in practice following the
recommendations of the manufacturers.
Methods
Participants were recruited through general practices in
Bedfordshire, Cornwall, Cumbria, Dumfries and Galloway, and
Surrey. The general practitioners were contacted by the study
coordinator or local study nurse and given full details of the
study with an invitation to take part. To widen participation to
reflect the broader community, school nurses placed posters in
local pharmacies and primary schools and the study nurses in
Surrey and Cumbria handed out information sheets at parents’
meetings.We aimed to recruit from families who would normally
go to their general practitioner for advice on head louse
treatment or would buy treatment from pharmacies. We had no
upper age limit for the study, but participants were aged up to 15
years. A lower age limit of 2 years was chosen for safety reasons.
The general practitioner or community nurse recruited
infested young people into the trial if they had a live head louse,
they had had no treatment for head lice in the previous three
weeks, they or their guardian agreed not to use other head louse
treatments during the trial, they or their guardian had provided
written informed consent, and the guardian agreed that the
immediate family would be examined for lice and, if necessary,
given the same treatment as allocated to the family member with
confirmed head louse infestation.
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Design
For ethical reasons, we did not use a conventional double blind,
randomised, placebo controlled trial. We therefore carried out a
randomised, comparative study of the Bug Buster kit against the
currently recommended insecticide products in any given area.
The specimen louse from the confirmed index case was removed
by the general practitioner or community nurse and stuck on a
record card for later confirmation by the local study nurse. Only
this one participant from each family who fulfilled the inclusion
criteria was included in later analysis after being randomly
assigned to one of two treatment arms: the Bug Buster kit (Com-
munity Hygiene Concern: London) or a proprietary bottle of
insecticide treatment containing either 0.5% aqueous malathion
(Derbac-M; Seton-Scholl Healthcare, Oldham) or aqueous
permethrin (1% Lyclear, crème rinse; Warner Lambert UK,
Eastleigh). We chose two different insecticides on pragmatic
grounds, as accessibility to treatment varies nationwide
according to local policy. We selected aqueous solutions of insec-
ticides as opposed to those with an alcohol base because they are
widely used formulations and are suitable for people with
asthma.
The Bug Buster kit is dispensed over the counter or through
mail order. A survey of 92 pharmacies in our study areas (NH,
unpublished data) found just 8% of outlets that offered the addi-
tional information of double dosing when a pediculicide was
purchased. For this reason we provided no additional
information on how to use the products other than that supplied
with the products. Participants allocated to the Bug Buster kit
used their own conditioner. The general practitioners stressed
the importance of checking for lice in family members and
reporting any finds. Each participating general practitioner was
assigned an individual randomisation list at the start of the trial,
generated using Minitab 11.0 for Windows, and provided with
supplies of the treatments.
Participants were visited at home by the study coordinator or
local study nurse or were asked to return to their surgery for
follow-up five days after application of the pediculicides or 15
days after the start of the Bug Buster regimen. We decided to use
different end points as the duration of treatments varied. We
chose day 5 for pediculicides and day 15 for the Bug Buster kit to
allow sufficient time for treatments to be completed and to pro-
vide a similar opportunity for reinfestation to occur (2-4 days
after completion of treatment in each case). We did not evaluate
ovicidal activity.
The study nurses attended a one day workshop on louse
detection using the wet combing with conditioner method
(combing wet and conditioned hair from root to tip across the
whole scalp with a fine toothed comb, then repeated in rinsed
hair). The nurses, unaware of treatment allocation, used this
method at each follow-up. They recorded the presence, number,
and stage of lice. From this we determined cure (no live lice) or
failure (one or more live lice). Lice were stored at − 20ûC for
detection of molecular or biochemical resistance mechanisms,
specifically kdr-type mutations from genomic DNA.14 Partici-
pants or their guardians in both groups completed a simple
questionnaire to determine compliance and satisfaction with the
treatment and to obtain basic epidemiological information,
including age, sex, number of siblings, history of head louse
infestation and treatment, and recent use of antibiotics.
Statistical analysis
We calculated that we would need a sample size of 98 (49 in each
arm) to detect a 30% difference between the two groups (80% for
one treatment, 50% for the other), with a power of 80% and 5%
significance (Stata 8.1). We analysed the data from those partici-
pants who completed the study and provided outcome data. We
carried out a univariate analysis using Yates corrected 2 test in
Epi Info (version 6) to test the effect of treatment type (the rela-
tive risk) on cure rate. To estimate the effect of missing data for
participants who were allocated treatment but did not complete
the study, we used extreme case analysis. The number needed to
treat was calculated.
Results
A total of 133 young people aged 2-15 years were recruited and
received treatment: 66 from Bedfordshire, 15 from Cornwall, 34
from Cumbria, 4 from Dumfries and Galloway, and 14 from Sur-
rey (figure). One participant from Surrey allocated the Bug
Buster kit was excluded for also using an insecticide, and six par-
ticipants were lost to follow-up (three each from Cumbria and
Surrey; five received the Bug Buster kit and one malathion). We
analysed the data on the remaining 126 participants who
completed the study: 56 were allocated to the Bug Buster kit, 40
to permethrin, and 30 to malathion. The characteristics of the
two groups were well matched at baseline (table 1).
The cure rates for malathion and permethrin were 17%
(5/30) and 10% (4/40). The cure rate for the Bug Buster kit was
significantly greater than that for the pediculicides (57% versus
13%; relative risk 4.4, 95% confidence interval 2.3 to 8.5; table 2).
The significant difference remained after extreme case analysis,
which included missing outcome data and assumed that all six
missing or excluded participants allocated the Bug Buster kit
were not cured but that the missing individual allocated insecti-
cide was—that is, cure rates of 52% (32/62) and 14% (10/71),
respectively (relative risk 3.7, 2.0 to 6.8). We determined that for
every two or three people using the Bug Buster kit rather than
pediculicides an extra person would be cured (number needed
to treat 2.26).
Head louse infestation occurred for the first time in 22% of
the young people examined. In families of young people with
previous head lice infestations, 55% usually went to their general
practice for a pediculicide prescription and the remainder
purchased treatment from a pharmacist or sought advice from
friends. We had no reports of recent antibiotic use and no
Participants randomised (n=133)
Assigned Bug Buster Kit (n=62)
Excluded (n=1)
Lost to follow-up (n=5)
Completed trial (n=56)
Lost to follow-up (n=1)
Completed trial (n=70)
Assigned pediculicide (n=71)
Flow of participants through trial
Table 1 Baseline descriptive characteristics of participants with outcome
data who were allocated to Bug Buster kit or pediculicide for eliminating
head lice
Characteristic Bug Buster kit (n=56) Pediculicide (n=70)
Mean (SD) age (years) 7.66 (2.62) 6.91 (2.42)
% (No) female 77 (43) 81 (57)
Mean (SD) No of children per
family
2.18 (0.94) 2.06 (0.92)
% (No) who had past
infestation
79 (44) 77 (54)
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reports of lice among the family members of recruits during the
trial.
Discussion
The Bug Buster kit was four times more effective than current
over the counter pediculicides for eliminating head lice. This
finding is contrary to a previous study in Wales in which
malathion treatment was twice as effective as the Bug Buster
regimen.10 It seems likely that the higher cure rate with the Bug
Buster kit in our study is a result of improvements to the fine
toothed comb, as this was the only major change. If so, it suggests
that the success of fine toothed combing depends on the choice
of comb. The effectiveness of the pediculicides was much lower
in our trial than in the Welsh trial, and much more in line with
the results from a previous trial in Bristol, which reported cure
rates of 13% for permethrin and 36% for malathion.4
This discrepancy may be accounted for in several ways.
Firstly, we used the manufacturer’s recommended single dose of
insecticide rather than two doses six days apart, which is now
considered an unlicensed use.15 Owing to the limited residual
effect, a double dose is likely to have greater success in killing
nymphs that emerge from eggs not destroyed by the first dose.
Secondly, our follow-up time was five days rather than seven days
after insecticide treatment, as in the Welsh trial, but this is
unlikely to have led to an underestimate of the cure rate given
the lack of a significant residual effect. A longer period before
measurement of outcomes increases the chance of nymphs
emerging and being detected, and also increases the risk of rein-
festation. Thirdly, we used an aqueous formulation rather than
an alcohol one so that we could include people with allergies.
The Welsh trial used either formulation, according to whether
participants had allergies, but did not report any difference in
effectiveness between the two. Fourthly, we recruited only people
whose lice infestation had been reported by their families, rather
than using school nurses to find cases by screening with fine
toothed combs as in the Welsh trial. Our study population was
reasonably representative of the population who normally seek
treatment for head lice, as the ratio of those who had previously
sought treatment from pharmacies or their doctors was similar
to that reported in the national population.17 For several reasons
we therefore believe our trial better reflects how over the counter
products are used in the community.
Finally, the discrepancy may also be due to differences in
resistance to insecticide, as our trial was carried out after the
Welsh trial and included a range of urban settings. The particu-
larly poor effectiveness of permethrin is likely to be due to wide-
spread kdr-type resistance; all but one of the lice from treatment
failures collected in this study were found to have the T929I and
L932F resistant genotype mutations of the paratype sodium
channel gene (MSW, unpublished data). On the basis of these
and earlier similar findings we believe that the status of licensed
insecticide treatments needs to be assessed as they potentially
expose users to repeat applications without any important
reduction in infestations.
The updated Bug Buster kit seems to provide a viable
alternative to over the counter insecticide treatments. An obser-
vational study in Ghent, Belgium reported promising findings
on satisfaction with wet combing as a treatment.18 In this study,
families of head lice infested schoolchildren were given impartial
advice on treatment options and then allowed to choose the
treatment; most chose wet combing with conditioner (29%) over
pediculicides (19%) or a combination of the two (15%), which
suggests the Bug Buster regimen may be readily taken up by the
community.
Some may consider that the cure rate of only 57% we
detected with the Bug Buster kit is still unacceptable and may not
provide an efficient treatment against head lice. At present there
are no readily available products that provide fully effective con-
trol of head lice, and there is an urgent need to identify safe,
novel insecticides of proved efficacy.
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Table 2 Outcome measures at follow-up for participants allocated Bug Buster kit or pediculicide for eliminating head lice
Analysis
Bug Buster kit (15 days) Pediculicide (5 days)
P value Relative risk (95% CI)Total % (No) cured Total Cured
Participants with complete outcome
data
56 57 (32) 70 13 (9) <0.0001 4.4 (2.3 to 8.5)
Assuming treatment failure for
participants with missing data
62 52 (32) 71 13 (9) <0.0001 4.1 (2.1 to 7.8)
Assuming treatment failure for
participants with missing data in
Bug Buster group but success in
insecticide group*
62 52 (32) 71 14 (10) <0.0001 3.7 (2.0 to 6.8)
*Extreme case analysis.
What is already known on this topic
Head lice have varying degrees of resistance to over the
counter pediculicides
Fine tooth combing of wet hair is an effective method of
detecting head lice but unproved as a treatment
What this study adds
Effectiveness of popular over the counter pediculicides for
eliminating head lice is poor
The kdr-type resistance mechanism to pyrethroids is
widespread in head lice in the United Kingdom
The Bug Buster kit is significantly more effective than
common over the counter pediculicides for normal
unsupervised use
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